Pathological MAPK activation–mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib is a research paper published in JCI Insight (2022). On theSindex it has a DataRank of 0. It has been cited 11 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: HL141377,HL118100
NHLBI NIH HHS
Grant: R01 HL118100
NIH HHS
Grant: S10 OD025113
NIH HHS
Grant: S10 OD021580
NHLBI NIH HHS
Grant: R01 HL141377
National Institutes of Health
Grant: 5R01HL141377-06
Epigenetic regulation of lymphatic development
National Institutes of Health
Grant: 5R01HL118100-07
Regulation of Cardiac Development by Chromatin Modifying Enzymes
National Institutes of Health
Grant: 1S10OD025113-01
Transmission Electron Microscope for Core EM Facility
National Institutes of Health
Grant: 1S10OD021580-01
Ultramicrotome
FWCI
1.90
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals